Personalized Medicine is upon us, as genome sequencing continues to expand, and approval of clinical tests multiply year over year. Key to this public health evolution are the molecular diagnostics driven by the model of Precision Medicine, the process of comprehensiveness, detail and exactness coupled to one’s individuality resulting from each unique genomic “blueprint”. These molecular diagnostics should offer meaningful clinical assessment of one’s health status at any point during their lifetime once that genomic blueprint is exposed to the environment and life itself. Biomarkers that accurately detect, diagnose, or better still, predict the onset of specific disease are the preliminary step to advancing clinical integration of such molecular diagnostics. These highly sought after and medically consequential diagnostic tests remain a crucial step for the future of healthcare as every individual’s genetics and lifestyle comingle indefinitely, for either good or bad.Several clearly defined disparities in bioinformatic capabilities that, if unresolved, will continue to impair the prospects for success of current and future global research efforts that rely on the integration of systems biology, diagnostic development, and drug discovery. Altomics Datamation is producing those innovative, knowledge creating tools for use by biomedical investigators in both academic and industrial environments. The company has amassed significant content, derived from data harvesting from numerous comprehensive government-academic-industry supported public data repositories. Most importantly, the information obtained has been reconfigured into a novel conceptual framework needed to derive answers to central scientific questions that impair biomarker discovery and their interpretation. This company is focused on the development of a suite informatic solutions needed for deep learning that bridges genomics and molecular phenotypes for complex polygenic diseases.

The desired clinical goal to improve risk prediction for cardiovascular disease (CVD) and the need for effective pharmacological intervention has reached an inflection point. Stymied by fifty years of scientific dogma and the absence of a compelling mechanistic model to supplant it, the research and clinical community are struggling to explain an increasing disconnect between the clinical biomarkers currently in use and disease outcomes. The impact of lipoprotein biology on cardiovascular health is not in dispute but their predictive value is being challenged. Recent experimental innovations have exposed a level of lipoprotein complexity unforeseen just a few years ago and an unprecedented increase in empirical data generated. HDL Apomics is taking an HDL-centric view for progressing our understanding of cardiovascular disease and its associated complications. The adage “if you can’t measure it, you won't manage it” is even more true in cardiovascular/metabolic disease than ever before. Importantly however, HDL is not an macromolecular entity that can be defined by a surrogate lipid. HDL is a complex heterogeneous population of particles in which major scientific, health, and commercial potential are concealed and remain to be realized. "Omics" research has defined an updated approach to HDL metrics and the paradigm shift away from HDL-C is inevitable. The methodological strategy we offer is unmatched in terms of platform technology and strategic insight. As a consequence of our assumed leadership position, we fully anticipate that our innovative approach to HDL measurement will drive scientific success in this key pharmacotherapeutic area for the coming decade. Our business model assures rapid self-sufficiency and revenue growth, as we envisage our IP will drive development of a multi-centric international network exploiting our technology in both the private sector and in academia.Funding:NHLBI SBIR Ph. I

The Schering-Plough merger with Merck resulted in a major loss of scientific innovation. I chose to resign following my reassignment to the Atherosclerosis group in Rahway, a department that lacked a strategic vision and was eliminated within two years.

Lab head and project leader in pre-clinical cardiovascular/metabolic research:- target identification and validation- bioinformatics and analytics- compound screening and lead discoverySpecializing in dislipidemia and atherosclerosis, lipoproteins, structure/function analysisDesigned and implemented strategy to identify and validate the molecular target of the blockbuster drug ezetimibe (Zetia/Vytorin). Conducted cell-based and mouse model mechanism of action (MOA) studies. Led NPC1L1-based compound screening for identification of new lead molecules for backup program. • SPRI President’s Award 2004Selected Publications: • Science 303:1201, 2004 • J. Biol. Chem 279:33586, 2004 • PNAS 102:8132, 2005 • Mol. Pharm. 71:19, 2007Patents: • 6,593,078 granted 2003 • 6,632,933 granted 2003 • 6,933,107 granted 2005 • 7,135,556 granted 2006 • 7,144,696 granted 2006 • 7,723,020 granted 2010 • 7,910,698 granted 2011 • 8,212,016 granted 2012App.No. 13/271,348 filed 10/12/11"NPC1L1 (NPC3) and methods of use thereof"Designed and implemented genome-wide RNAi screening strategy to identify proteins responsible for the regulation of apolipoprotein A-I protein expression and secretion.Patents:• 8,257,921 granted 2012Designed and implemented functional screen program to identify, validate and characterize small molecule inhibitors of intestinal fructose uptake transporters Glut 2 and Glut5.Designed and implemented compound library screen for molecules modulating leptin/leptin-R interactions.

• Molecular analysis of cytokine - receptor interactions• Rational design of cytokine receptor antagonists.Selected Publications:• Growth Factors 12:231, 1995• J. Biol. Chem. 27:2233, 1995Patents:• 6,225,446 granted 2001